Improved Therapies with Potential Results With small changes, MIRA’s technology focuses on big effects that have the potential to redefine therapeutic outcomes, opening up new markets for …

15 小时之前 · The transaction includes a $5 million capital infusion-comprised of cash or equivalent consideration-into MIRA, reinforcing its financial position and supporting the …

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and …

15 小时之前 · On Monday, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The transaction includes a $5 million …

14 小时之前 · Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. …

1 天前 · MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug …

1 天前 · MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid …

14 小时之前 · MIRA Pharmaceuticals secures a $5M infusion with SKNY acquisition to advance SKNY-1 for weight loss & smoking cessation.

1 天前 · MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio.

MIRA-55, a revolutionary new compound, solves three central challenges in cannabinoid drug development. How to enhance the beneficial effects of THC and CBD compounds. How to …